Letter to the Editor: "Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin".
作者信息
Taylor Simeon I
机构信息
University of Maryland School of Medicine, Department of Medicine, Division of Endocrinology, Diabetes, and Nutrition, Baltimore, Maryland.
出版信息
J Endocr Soc. 2020 Feb 29;4(3):bvaa005. doi: 10.1210/jendso/bvaa005. eCollection 2020 Mar 1.
Abstract
摘要
相似文献
1
Letter to the Editor: "Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin".致编辑的信：“高血压和2型糖尿病与西他列汀对二肽基肽酶-4的抑制作用降低有关”
J Endocr Soc. 2020 Feb 29;4(3):bvaa005. doi: 10.1210/jendso/bvaa005. eCollection 2020 Mar 1.
2
Response to Letter to the Editor: "Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin".对致编辑信的回复：“高血压和2型糖尿病与西他列汀对二肽基肽酶-4的抑制作用降低有关”
J Endocr Soc. 2020 Feb 29;4(3):bvaa006. doi: 10.1210/jendso/bvaa006. eCollection 2020 Mar 1.
3
Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease.西他列汀慢性二肽基肽酶-4 抑制作用与 2 型糖尿病和冠心病患者的缺血性左心室功能障碍的持续保护相关：一项初步研究。
Circ Cardiovasc Imaging. 2014 Mar;7(2):274-81. doi: 10.1161/CIRCIMAGING.113.000785. Epub 2014 Feb 6.
4
Critical role of renal dipeptidyl peptidase-4 in ameliorating kidney injury induced by saxagliptin in Dahl salt-sensitive hypertensive rats.肾二肽基肽酶-4在改善沙格列汀诱导的Dahl盐敏感型高血压大鼠肾损伤中的关键作用
Eur J Pharmacol. 2015 Aug 15;761:109-15. doi: 10.1016/j.ejphar.2015.04.023. Epub 2015 May 1.
5
Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats.二肽基肽酶-IV抑制可预防1型糖尿病大鼠视网膜的血视网膜屏障破坏、炎症和神经元细胞死亡。
Biochim Biophys Acta. 2014 Sep;1842(9):1454-63. doi: 10.1016/j.bbadis.2014.04.013. Epub 2014 Apr 25.
6
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.2型糖尿病患者口服葡萄糖耐量试验后，单剂量口服二肽基肽酶-4抑制剂西他列汀对肠促胰岛素和血糖水平的影响。
J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9. doi: 10.1210/jc.2006-1009. Epub 2006 Aug 15.
7
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes.西他列汀，一种二肽基肽酶-4 抑制剂，可降低 2 型糖尿病伴高血压的日本患者的收缩压。
Tohoku J Exp Med. 2011 Feb;223(2):133-5. doi: 10.1620/tjem.223.133.
8
Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism.曲格列汀（SYR-472，Zafatek），一种新型的2型糖尿病每周一次治疗药物，通过非共价机制抑制二肽基肽酶-4（DPP-4）。
PLoS One. 2016 Jun 21;11(6):e0157509. doi: 10.1371/journal.pone.0157509. eCollection 2016.
9
Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism.二肽基肽酶 4 抑制剂西他列汀通过胰高血糖素样肽 1 依赖机制保护高血压患者的血管内皮功能。
Hypertension. 2012 Sep;60(3):833-41. doi: 10.1161/HYPERTENSIONAHA.112.195115. Epub 2012 Aug 6.
10
Dipeptidyl peptidase-4 inhibitor sitagliptin improves pancreatic β-cell function in hypertensive diabetic patients treated with angiotensin receptor blockers.二肽基肽酶-4抑制剂西他列汀可改善接受血管紧张素受体阻滞剂治疗的高血压糖尿病患者的胰腺β细胞功能。
J Renin Angiotensin Aldosterone Syst. 2015 Dec;16(4):1001-9. doi: 10.1177/1470320315587180. Epub 2015 Jul 20.
本文引用的文献
1
Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin.高血压和2型糖尿病与西他列汀对二肽基肽酶-4抑制作用降低有关。
J Endocr Soc. 2017 Aug 1;1(9):1168-1178. doi: 10.1210/js.2017-00312. eCollection 2017 Sep 1.
2
Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin.西格列汀、沙格列汀或维格列汀治疗的 2 型糖尿病患者的二肽基肽酶-4 抑制作用。
Diabetes Ther. 2013 Dec;4(2):431-42. doi: 10.1007/s13300-013-0045-8. Epub 2013 Oct 26.
3
Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.沙格列汀对二肽基肽酶4（DPP4）的效力、选择性及长效结合作用：与一种快速解离的DPP4抑制剂相比，沙格列汀在体外和体内维持对DPP4的抑制作用。
BMC Pharmacol. 2012 Apr 4;12:2. doi: 10.1186/1471-2210-12-2.
4
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.2型糖尿病患者口服葡萄糖耐量试验后，单剂量口服二肽基肽酶-4抑制剂西他列汀对肠促胰岛素和血糖水平的影响。
J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9. doi: 10.1210/jc.2006-1009. Epub 2006 Aug 15.
5
Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects.口服二肽基肽酶-4抑制剂西他列汀在中年肥胖受试者中的药代动力学和药效学效应
J Clin Pharmacol. 2006 Aug;46(8):876-86. doi: 10.1177/0091270006289850.
6
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.二肽基肽酶IV抑制剂西他列汀在健康受试者中的药代动力学和药效学：两项单次口服剂量随机、双盲、安慰剂对照研究的结果
Clin Pharmacol Ther. 2005 Dec;78(6):675-88. doi: 10.1016/j.clpt.2005.09.002.
7
Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema.血管紧张素转换酶抑制剂相关性血管性水肿患者的二肽基肽酶IV活性
Hypertension. 2002 Feb;39(2 Pt 2):460-4. doi: 10.1161/hy0202.103054.
Zotero 插件